Deep-Dive Due Diligence AI Generated Report on Aptorum Group Limited Class A Ordinary Shares (APM)
Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.
These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
45
$1.30
20
Speculative
Mixed
Earnings report
C
BIOTECH, VOLATILE, HIGH RISK, SALES DECLINE, MARKET FLUCTUATION
APTORUM SURGES AMIDST VOLATILITY, SALES DECLINE RAISES CONCERNS
APM_OUT_1 [2025-04-15 14:45:32 -0400] 4038 Bytes | 1057 tokens | Cum: 1057 tkns (13.21% of 8k)
==========================================================================
You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Aptorum (APM) hit my radar screen, up to 1.1250 from a prev close of 0.8150 Do you think its got more juice or is it lacking potential? It's 2:45:32 PM on Tue Apr 15, 2025 -0400 and I have to decide: buy or sell!
--- COMPANY PROFILE ---
Company: Aptorum (APM)
IPO: 2018-12-18 (6 Years Ago)
Market Cap: $6,612,261
Shares Outstanding: 5,350,000
Exchange: XNAS
Description: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Here’s a list of headlines for Aptorum:
Jan-08-25 06:28AM - Aptorum Group to Issue 1.5 Million Class A Shares
Jan-02-25 10:55AM - Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
Dec-31-24 10:17AM - Why Aptorum Group (APM) Jumped Nearly 300% at Pre-Market Trading
Dec-20-24 04:00PM - Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
Apr-30-24 09:15AM - Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
Apr-12-24 06:40AM - 7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Mar-06-24 08:00AM - Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
Dec-22-23 04:30PM - Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.
B1 - 2025-01-02T15:55:00Z - Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
B2 - 2024-03-14T17:38:41Z - Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B3 - 2024-03-14T13:46:43Z - US Stocks Higher; Producer Prices Rise 0.6% In February
B4 - 2024-03-07T18:35:19Z - Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B5 - 2024-03-07T14:54:39Z - Nasdaq Rises 100 Points; BJ's Wholesale Posts Weak Sales
B6 - 2024-03-07T13:05:46Z - Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
==============
-> THE ROLE FOR AI:
==============
1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Aptorum (APM).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.
2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.
3) You will request information by referencing documents by their code.
4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:
5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.
NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`
APM_IN_2 [2025-04-15 14:45:32 -0400] 2 Bytes | 2 tokens | Cum: 1059 tkns (13.24% of 8k)
==========================================================================
B1
APM_OUT_3 [2025-04-15 14:45:34 -0400] 831 Bytes | 228 tokens | Cum: 1287 tkns (16.09% of 8k)
==========================================================================
Showing B1 (chunk 1 of 1): B1:
**Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/02/3003612/0/en/Aptorum-Group-Limited-Announces-Pricing-of-3-0-Million-Registered-Direct-Offering.htmlAptorum Group, a clinical-stage biopharmaceutical company, announced a $3 million registered direct offering of 1,535,000 Class A Ordinary Shares at $2.00 per share. The offering is expected to close on January 3, 2025, subject to customary closing conditions.
Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.
APM_IN_4 [2025-04-15 14:45:34 -0400] 3 Bytes | 2 tokens | Cum: 1289 tkns (16.11% of 8k)
==========================================================================
NEX
APM_OUT_5 [2025-04-15 14:45:36 -0400] 511 Bytes | 130 tokens | Cum: 1419 tkns (17.74% of 8k)
==========================================================================
We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.
A1 - 2025-04-15T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Apt...
Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.
APM_IN_6 [2025-04-15 14:45:36 -0400] 2 Bytes | 2 tokens | Cum: 1421 tkns (17.76% of 8k)
==========================================================================
A1
APM_OUT_7 [2025-04-15 14:45:37 -0400] 1181 Bytes | 349 tokens | Cum: 1770 tkns (22.12% of 8k)
==========================================================================
Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - Dogwood Therapeutics (NASDAQ:DWTX), Aptorum Gr (NASDAQ:APM)**Date: 2025-04-15Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44820863/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers Mural Oncology MURA stock increased by 145.5% to $2.53 during Tuesday's regular session. The market value of their outstanding shares is at $43.5 million. Skye Bioscience SKYE stock moved upwards by 36.64% to $1.79. The market value of their outstanding shares is at $55.4 million. Dogwood Therapeutics DWTX stock moved upwards by 32.57% to $3.98. The company's market cap stands at $7.6 million. Phio Pharma PHIO shares increased by 29.47% to $2.85. The market value of their outstanding shares is at $13.6 million. Verve Therapeutics VERV shares increased
Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.
APM_IN_8 [2025-04-15 14:45:37 -0400] 3 Bytes | 2 tokens | Cum: 1772 tkns (22.15% of 8k)
==========================================================================
MOR
APM_OUT_9 [2025-04-15 14:45:40 -0400] 1181 Bytes | 358 tokens | Cum: 2130 tkns (26.62% of 8k)
==========================================================================
Showing A1 (chunk 2 of 3): by 24.51% to $5.13. The company's market cap stands at $455.5 million. Aptorum Gr APM stock rose 21.12% to $0.99. The company's market cap stands at $7.0 million. Losers Spruce Biosciences SPRB stock declined by 55.9% to $0.14 during Tuesday's regular session. The market value of their outstanding shares is at $5.7 million. The company's, Q4 earnings came out today. MetaVia MTVA stock declined by 37.78% to $1.15. The company's market cap stands at $9.9 million. MSP Recovery MSPR shares decreased by 22.27% to $2.2. The market value of their outstanding shares is at $4.6 million. Impact BioMedical IBO shares declined by 22.26% to $0.37. The market value of their outstanding shares is at $4.2 million. Geovax Labs GOVX shares decreased by 21.73% to $0.84. The company's market cap stands at $7.9 million. Sharps Technology STSS stock fell 19.3% to $0.03. See Also: www.benzinga.com/money/best-h
Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.
APM_IN_10 [2025-04-15 14:45:40 -0400] 3 Bytes | 2 tokens | Cum: 2132 tkns (26.65% of 8k)
==========================================================================
NEX
APM_OUT_11 [2025-04-15 14:45:42 -0400] 238 Bytes | 59 tokens | Cum: 2191 tkns (27.39% of 8k)
==========================================================================
This is our list of SEC filings.
If empty, the search returned no recent filings.
Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
APM_IN_12 [2025-04-15 14:45:42 -0400] 16 Bytes | 3 tokens | Cum: 2194 tkns (27.43% of 8k)
==========================================================================
Could you please
APM_OUT_13 [2025-04-15 14:45:42 -0400] 251 Bytes | 78 tokens | Cum: 2272 tkns (28.40% of 8k)
==========================================================================
You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source
You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.
APM_IN_14 [2025-04-15 14:45:42 -0400] 13 Bytes | 3 tokens | Cum: 2275 tkns (28.44% of 8k)
==========================================================================
It seems like
APM_OUT_15 [2025-04-15 14:45:54 -0400] 4904 Bytes | 1169 tokens | Cum: 3444 tkns (43.05% of 8k)
==========================================================================
This is our set of metrics for Aptorum.
Please analyze the numbers.
+--------------------+-----------------------+------------------------+-------------------------+
| Volume: 665,076 | Perf Month: 10.20% | Option/Short: No / Yes | Sales Y/Y TTM: -100.00% |
+--------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 87.59K | Perf Quarter: -15.50% | Short Float: 0.52% | ROE: 0.08% |
+--------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 9.76 | Index: - | Short Ratio: 0.27 | ROI: 0.07% |
+--------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 63.22 | Market Cap: 7.42M | Short Interest: 0.02M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.11 | Shs Outstand: 7.14M | Beta: -0.29 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA20: 22.79% | Shs Float: 4.57M | Sales Q/Q: -100.00% | P/E: 55.58 |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA50: 5.75% | Inst Own: 6.04% | Sales past 5Y: - | Earnings: Dec 20 AMC |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA200: -42.11% | Insider Own: 35.96% | Employees: - | |
+--------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 41.80% | Insider Trans: 0.00% | Debt/Eq: 0.15 | |
+--------------------+-----------------------+------------------------+-------------------------+
The next section covers any insider trading by Aptorum officers or majority shareholders (if available).
[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A
[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A
[Price Metrics - Last 30 Days]
Latest Close: 1.14
Average Volume: 58612.91
30-Day High: 1.14
30-Day Low: 0.71
No detailed financial data available.
==== END OF FINANCIAL REPORT ====
You are now requested to write a summary analysis of Aptorum (APM).
Please complete the report using the exact format:
FIELD[value]
1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Aptorum.
2) MARKET_SCORE[]
This conversation was initiated because APM is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for APM.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.
3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, APM could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect APM to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]
4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.
5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.
6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)
7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.
8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.
9) SENTIMENT[]
bullish, bearish, neutral, or mixed
10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Aptorum.
11) ETHICAL_RATING[]
Rate Aptorum’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.
12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Aptorum.
Provide any reasons you can use to support it.
Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.
Finally, thank you for participating!
APM_IN_16 [2025-04-15 14:45:54 -0400] 1098 Bytes | 241 tokens | Cum: 3685 tkns (46.06% of 8k)
==========================================================================
BRIEF_SUMMARY[Aptorum has shown significant short-term volatility with a sharp increase in performance over the past week, although it faces challenges with a steep decline in sales year-over-year and a concerning sales performance. Despite a recent surge in stock price and volume, the company's long-term financial health is questionable, marked by a 100% drop in sales both quarterly and year-over-year, a low market cap, and minimal institutional ownership.]
MARKET_SCORE[45]
PRICE_TARGET[1.30]
AI_RPT_HEADLINE[Aptorum Surges Amidst Volatility, Sales Decline Raises Concerns]
SQUEEZE_POTENTIAL[20]
TAGS[biotech, volatile, high risk, sales decline, market fluctuation]
STOCK_TYPE[speculative]
PRIMARY_CATALYST[earnings report]
SENTIMENT[mixed]
IMPROVEMENT_SUGGESTION[More detailed financials, including breakdown of revenue streams and operational costs, would enhance analysis.]
ETHICAL_RATING[C]
UPCOMING_CATALYST[Earnings report on December 20 could significantly impact stock performance, either positively or negatively, depending on the results and management's future outlook.]
APM_IN_17 [2025-04-15 14:45:54 -0400] 126 Bytes | 29 tokens | Cum: 3714 tkns (46.42% of 8k)
==========================================================================
====================================
[2025-04-15 14:45:54] # Analysis Completed
Elapsed Time: 22.43 seconds